HC Wainwright Has Lowered Expectations for Inovio Pharmaceuticals (NASDAQ:INO) Stock Price

Inovio Pharmaceuticals (NASDAQ:INO) had its target price reduced by HC Wainwright from $12.00 to $5.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 24.07% from the company’s previous close.

INO has been the subject of a number of other research reports. Oppenheimer dropped their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday. Royal Bank of Canada dropped their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $38.00.

Inovio Pharmaceuticals Stock Down 1.1 %

INO stock opened at $4.03 on Monday. The business has a 50-day simple moving average of $5.66 and a 200 day simple moving average of $8.03. Inovio Pharmaceuticals has a 52 week low of $3.85 and a 52 week high of $14.75.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in shares of Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 3,630 shares during the period. MetLife Investment Management LLC increased its stake in shares of Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 8,546 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $82,000. Signature Estate & Investment Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals in the second quarter valued at approximately $88,000. Finally, American Century Companies Inc. increased its stake in shares of Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares during the period. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.